New treatment for acute myelogenous leukemia

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 1, 2015, Pages 95-106

  DiNardo, Courtney D ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Future directions; Targeted therapy; Treatment review

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CLADRIBINE; CYTARABINE; ELACYTARABINE; FLAVOPIRIDOL; GEMTUZUMAB OZOGAMICIN; MIDOSTAURIN; MONOCLONAL ANTIBODY; PRACINOSTAT; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; SAPACITABINE; SORAFENIB; VALPROIC ACID; VENETOCLAX; VOLASERTIB; VORINOSTAT; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER THERAPY; EPIGENETICS; EXPECTATION; HUMAN; IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; CLINICAL TRIAL (TOPIC); GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 84917708460     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.981527     Document Type: Review

References (91)

1. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 2011;105(11):1684-92
2. Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012;119(1):34-43
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA 2013;63(1):11-30
4. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC- 63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer chemotherapy reports Part 1 1973;57(4):485-8
5. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60(2):454-62
6. Shah A, Andersson TM, Rachet B, et al. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol 2013;162(4):509-16
7. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107(9):3481-5
8. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106(5):1090-8
9. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162(14):1597-603
10. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98(5):1312-20
11. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006;108(10):3280-8
12. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369(2):111-21
13. Inagaki A, Nakamura T, Wakisaka G. Studies on the mechanism of action of 1-beta-D-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes. Cancer Res 1969;29(12):2169-76
14. Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 1998;72:197-233
15. Carson DA, Wasson DB, Butler E. Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc Nat Acad Sci USA 1984;81(7):2232-6
16. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322(16):1117-21
17. Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 1993;10(Suppl):109-14
18. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012;30(20):2441-8
19. Kantarjian HM, Garcia-Manero G, Luger S, et al. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. ASH Annual Meeting Abstracts 2009;114(22):1061
20. Luger SM, Goldberg S, Altman JK, et al. editors. A randomized Phase II study of sapacitabine in mds refractory to hypomethylating agents. 2012 ASCO Annual Meeting 2012;30(Suppl):abstract 6520
21. Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabineresistant lymphoma cell lines. Br J Haematol 2009;144(2):273-5
22. Bergman AM, Kuiper CM, Myhren F, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1523-6
23. Adema AD, Losekoot N, Smid K, et al. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP- 4055) in CEM leukemic cells. Nucleosides Nucleotides Nucleic Acids 2010;29(4-6):394-9
24. DiNardo CD, O'Brien S, Gandhi VV, Ravandi F. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol 2013;9(8):1073-82
25. Roboz GJ, Rosenblat T, Arellano M, et al. International randomized Phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol 2014;32(18):1919-26
26. Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010;34(9):1214-23
27. Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011;29(8):979-85
28. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014;123(21):3239-46
29. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23(9):1969-78
30. Freeman C, Keane N, Swords R, Giles F. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opin Pharmacother 2013;14(10):1417-27
31. Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol 2009;64(1):53-65
32. Abbas JA, Stuart RK. Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs 2012;21(8):1223-33
33. Ravandi F, Kantarjian HM, Cripe LD, et al. A Phase 2 dose regimen optimization study of three schedules of voreloxin as single agent therapy for elderly patients with newly diagnosed acute myeloid leukemia. ASH Annual Meeting Abstracts 2009;114(22):1037
34. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nature reviews Drug Discov 2010;9(8):643-60
35. Janning M, Fiedler W. Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncol 2014;10(7):1157-65
36. Maertens J, Lubbert M, Fiedler W, et al. Phase I/II study of volasertib (BI 6727), an intravenous polo-like kinase (plk) inhibitor, in patients with Acute Myeloid Leukemia (AML): results from the randomized phase ii part for volasertib in combination with Low-Dose Cytarabine (LDAC) versus LDAC monotherapy in patients with previously untreated aml ineligible for intensive treatment. ASH Annual Meeting Abstracts 2012;120(21):411
37. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57(16):3375-80
38. Karp JE, Ross DD, Yang W, et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res 2003;9(1):307-15
39. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-Darabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005;11(23):8403-12
40. Karp JE, Blackford A, Smith BD, et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res 2010;34(7):877-82
41. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clinical Cancer Res 2007;13(15 Pt 1):4467-73
42. Zeidner JF, Gerber JM, Blackford A, et al. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 years and under with newly diagnosed Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts 2012;120(21):47
43. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9
44. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30(21):2670-7
45. Kantarjian HM, Roboz GJ, Rizzieri DA, et al. Results from the dose escalation phase of a randomized Phase 1-2 First-in-Human (FIH) study of SGI-110, a novel low volume stable Subcutaneous (SQ) Second generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. ASH Annual Meeting Abstracts 2012;120(21):414
46. Jabbour E, Yee K, Kropf P, et al. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), in adult patients with Acute Myeloid Leukemia (AML). 55th Annual Meeting and Exposition American Society of Hematology. 9 December 2013
47. Jayaraman R, Pilla Reddy V, Pasha MK, et al. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos 2011;39(12):2219-32
48. Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 2014;143(3):323-36
49. Quintas-Cardama A, Kantarjian HM, Ravandi F, et al. Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor pracinostat (SB939) and 5- Azacitidine in high-risk myelodysplastic syndrome. ASH Annual Meeting Abstracts 2012;120(21):3821
50. Kadia TM, Yang H, Ferrajoli A, et al. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 2010;150(1):72-82
51. Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012;30(18):2204-10
52. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/ 2 study of the combination of 5-aza-2'- deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108(10):3271-9
53. Tassara M, Dohner K, Brossart P, et al. Valproic acid in combination with alltrans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 2014;123(26):4027-36
54. Pemmaraju N, Kantarjian H, Andreeff M, et al. Investigational FMSlike tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs 2014;23(7):943-54
55. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
56. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
57. Haraldsdottir S, Shah MH. An update on clinical trials of targeted therapies in thyroid cancer. Curr Opin Oncol 2014;26(1):36-44
58. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100(3):184-98
59. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96(1):62-8
60. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28(11):1856-62
61. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013;31(25):3110-18
62. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121(23):4655-62
63. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105(1):54-60
64. Nazha A, Kantarjian HM, Borthakur G, et al. A Phase I/II Trial of combination of midostaurin (PKC412) and 5- Azacytidine (5-AZA) for the treatment of patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). ASH Annual Meeting Abstracts 2012;120(21):3587
65. Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26(9):2061-8
66. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114(14):2984-92
67. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013;31(29):3681-7
68. Cortes JE, Perl AE, Dombret H, et al. Final Results of a Phase 2 open-label, monotherapy efficacy and safety study of Quizartinib (AC220) in patients >= 60 years of age with FLT3 ITD positive or negative Relapsed/Refractory Acute Myeloid Leukemia. ASH Annual Meeting Abstracts 2012;120(21):48
69. Levis MJ, Perl AE, Dombret H, et al. Final results of a Phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/ refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. ASH Annual Meeting Abstracts 2012;120(21):673
70. Tallman MS, Schiller G, Trone D, et al. Results of a Phase 2 randomized, openlabel, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory Acute Myeloid Leukemia (AML). ASH 55th Annual Meeting 7-10 December 2013; New Orleans, LA
71. Bowen D, Russell N, Knapper S, et al. AC220 (Quizartinib) can be safely combined with conventional chemotherapy in older patients with newly diagnosed acute myeloid leukaemia: experience from the AML18 pilot trial. 55th ASH Annual Meeting and Exposition 2013
72. Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Nat Acad Sci USA 2014;111(14):5319-24
73. Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistanceconferring point mutants. Blood 2014;123(1):94-100
74. Alvarado Y, Kantarjian HM, Luthra R, et al. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 2014;120(14):2142-9
75. Collins R, Kantarjian HM, Levis MJ, et al. Clinical activity of Crenolanib in patients with D835 mutant FLT3- positive relapsed/refractory acute myeloid leukemia (AML). ASCO Meeting Abstracts 2014;32(5 Suppl):7027
76. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202-8
77. Debose L, Benito JM, Golfman LS, et al. BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia. Blood 2013;122:21
78. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014;4(3):362-75
79. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013;121(24):4917-24
80. Ward PS, Lu C, Cross JR, et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 2013;288(6):3804-15
81. Wang F, Travins J, Chen Y, et al. AG-221 offers a survival advantage in a primary Human IDH2 mutant AML xenograft model. AACR Annual Meeting; 5-9 April 2014; San Diego, CA
82. Mutant IDH2 inhibitor looks promising in AML. Cancer Discov 2014;4(6):OF9
83. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16(9):1627-36
84. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Res 2001;7(6):1490-6
85. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121(24):4854-60
86. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30(32):3924-31
87. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379(9825):1508-16
88. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27(4):504-10
89. Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122(8):1455-63
90. Larkin K, Blum W. Novel therapies in AML: reason for hope or just hype? American Society of Clinical Oncology educational book/ ASCO American Society of Clinical Oncology Meeting 2014. e341-51
91. Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD- 1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014;28(6):1280-8